At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Chikungunyabiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-label Study to Assess the Safety and Immunogenicity of an Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) in Prior Recipients of Other Alphavirus Vaccines Versus Alphavirus Naïve Controls.
In Brief
A Phase 2 clinical trial evaluating Chikungunya for Chikungunya. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
This was a phase 2 parallel-group age- and gender-matched open label study in healthy adults 18-65 years of age to assess the safety and immunogenicity of an alum-adjuvanted chikungunya virus-like particle vaccine (PXVX0317; CHIKV VLP vaccine) in prior recipients of other alphavirus vaccines versus alphavirus naïve controls.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChikungunya
CountriesUnited States
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartNov 2019
Primary CompletionJan 2021
TodayJul 2026
First PostedJun 20, 2019
Enrollment StartNov 20, 2019
Primary CompletionJan 19, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.0 years ago
Interventions
Chikungunyabiological
Virus Like Particle